Newsletter | May 24, 2021

05.24.21 -- Process Intensification: Best Practices For Implementing

Bioprocess Intensification: Fast, Flexible, And Efficient Solutions

Now that the biopharmaceutical industry has embraced single-use systems, the focus is shifting to process intensification, which has been defined in many ways. This compilation of articles details how industry experts define process intensification and how end users can transition toward continuous processing.

Integrated Platform For Intelligent Upstream Process Intensification

Biopharmaceutical manufacturers face pressure to increase production within their facilities while also accommodating less-stable molecules not suitable for standard fed-batch platforms. In this webinar, industry expert Gerben Zijlstra walks through a product life cycle, focusing on upstream process intensification and how process analytical technology (PAT) and perfusion-based tools are critical components of any solution.

Selecting The Optimal Upstream And Downstream Intensification Strategy

To meet the demands of next-generation biomanufacturing the industry will need multiple intensified strategies for upstream and downstream processes. Hear from industry expert Priyanka Gupta as she explains how intensified solutions for upstream and downstream processes can increase productivity by 4X and reduce up-front investment by 50%.

Real-World Experience: Modular Facilities, Smaller Footprint With Dynamic Perfusion

Established manufacturers are looking to single-use, flexible solutions when building new facilities or modifying existing operations. Their goal is to increase productivity across different modalities, including difficult-to-express molecules. Read this success story to understand how dynamic perfusion enabled a CDMO to increase throughput dramatically while establishing a multimodality facility.

Intensified Seed Train Strategy For Faster, Cost-Effective Scale-Up Of Biologics Manufacturing

The biopharmaceutical industry is looking at process intensification to cost-effectively produce monoclonal antibodies (mAbs). This article explores intensified processing of Chinese hamster ovary clones in the seed train of upstream cell cultures to support generation of high-cell-density cell banks and increased production of mAbs.